Celgene Corp. made a leap forward in its pursuit to become the global leader in hematology cancer therapies through its proposed $640 million acquisition of smallish biotech Gloucester Pharmaceuticals Inc., whose histone deacetylase inhibitor Istodax (romidepsin) last month gained FDA approval as a therapy for previously treated patients with cutaneous T-cell lymphoma (CTCL). (BioWorld Today) Read More
